On December 13, 2023, Novozymes and Chr. Hansen announced that the merged company will be named “Novonesis”, which signifies a “new starting point” and is derived from the Greek word “genesis”. This name symbolizes the arrival of a new era in biotechnological solutions, where innovation in biotechnology will provide solutions to a range of significant challenges faced by humanity.
The merger approval process is progressing smoothly as planned, and it is expected that, upon regulatory approval, the transaction will be completed in the first quarter of 2024. The name Novonesis will be used and gradually implemented after the proposed merger is completed. Until then, Novozymes and Chr. Hansen will continue to operate as completely independent companies. (Source: sohu.com)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE